Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2003 Jun;62(6):497–498. doi: 10.1136/ard.62.6.497

Fenofibrate and losartan

T Bardin 1
PMCID: PMC1754575  PMID: 12759281

Full Text

The Full Text of this article is available as a PDF (66.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bastow M. D., Durrington P. N., Ishola M. Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism. 1988 Mar;37(3):217–220. doi: 10.1016/0026-0495(88)90098-4. [DOI] [PubMed] [Google Scholar]
  2. Burnier M., Roch-Ramel F., Brunner H. R. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996 Jun;49(6):1787–1790. doi: 10.1038/ki.1996.268. [DOI] [PubMed] [Google Scholar]
  3. Burnier M., Rutschmann B., Nussberger J., Versaggi J., Shahinfar S., Waeber B., Brunner H. R. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension. 1993 Sep;22(3):339–347. doi: 10.1161/01.hyp.22.3.339. [DOI] [PubMed] [Google Scholar]
  4. Cappuccio F. P., Strazzullo P., Farinaro E., Trevisan M. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA. 1993 Jul 21;270(3):354–359. [PubMed] [Google Scholar]
  5. Culleton B. F., Larson M. G., Kannel W. B., Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999 Jul 6;131(1):7–13. doi: 10.7326/0003-4819-131-1-199907060-00003. [DOI] [PubMed] [Google Scholar]
  6. Desager J. P., Hulhoven R., Harvengt C. Uricosuric effect of fenofibrate in healthy volunteers. J Clin Pharmacol. 1980 Oct;20(10):560–564. doi: 10.1002/j.1552-4604.1980.tb01670.x. [DOI] [PubMed] [Google Scholar]
  7. Elisaf M., Tsimichodimos V., Bairaktari E., Siamopoulos K. C. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J Cardiovasc Pharmacol. 1999 Jul;34(1):60–63. doi: 10.1097/00005344-199907000-00010. [DOI] [PubMed] [Google Scholar]
  8. Enomoto Atsushi, Kimura Hiroaki, Chairoungdua Arthit, Shigeta Yasuhiro, Jutabha Promsuk, Cha Seok Ho, Hosoyamada Makoto, Takeda Michio, Sekine Takashi, Igarashi Takashi. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002 Apr 14;417(6887):447–452. doi: 10.1038/nature742. [DOI] [PubMed] [Google Scholar]
  9. Fang J., Alderman M. H. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000 May 10;283(18):2404–2410. doi: 10.1001/jama.283.18.2404. [DOI] [PubMed] [Google Scholar]
  10. Ferris T. F., Gorden P. Effect of angiotensin and norepinephrine upon urate clearance in man. Am J Med. 1968 Mar;44(3):359–365. doi: 10.1016/0002-9343(68)90107-1. [DOI] [PubMed] [Google Scholar]
  11. Grossman E., Peleg E., Carroll J., Shamiss A., Rosenthal T. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens. 1994 Dec;7(12):1041–1044. doi: 10.1093/ajh/7.12.1041. [DOI] [PubMed] [Google Scholar]
  12. Harvengt C., Heller F., Desager J. P. Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias. Artery. 1980;7(1):73–82. [PubMed] [Google Scholar]
  13. Hepburn A. L., Kaye S. A., Feher M. D. Fenofibrate: a new treatment for hyperuricaemia and gout? Ann Rheum Dis. 2001 Oct;60(10):984–986. doi: 10.1136/ard.60.10.984a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Liang M. H., Fries J. F. Asymptomatic hyperuricemia: the case for conservative management. Ann Intern Med. 1978 May;88(5):666–670. doi: 10.7326/0003-4819-88-5-666. [DOI] [PubMed] [Google Scholar]
  15. Mazzali M., Hughes J., Kim Y. G., Jefferson J. A., Kang D. H., Gordon K. L., Lan H. Y., Kivlighn S., Johnson R. J. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001 Nov;38(5):1101–1106. doi: 10.1161/hy1101.092839. [DOI] [PubMed] [Google Scholar]
  16. Mazzali Marilda, Kanellis John, Han Lin, Feng Lili, Xia Yi-Yang, Chen Qiang, Kang Duk-Hee, Gordon Katherine L., Watanabe Susumu, Nakagawa Takahiko. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002 Jun;282(6):F991–F997. doi: 10.1152/ajprenal.00283.2001. [DOI] [PubMed] [Google Scholar]
  17. Minghelli G., Seydoux C., Goy J. J., Burnier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation. 1998 Jul 27;66(2):268–271. doi: 10.1097/00007890-199807270-00023. [DOI] [PubMed] [Google Scholar]
  18. Nakashima M., Uematsu T., Kosuge K., Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 1992;42(3):333–335. doi: 10.1007/BF00266358. [DOI] [PubMed] [Google Scholar]
  19. Puig J. G., Mateos F., Buño A., Ortega R., Rodriguez F., Dal-Ré R. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens. 1999 Jul;17(7):1033–1039. doi: 10.1097/00004872-199917070-00021. [DOI] [PubMed] [Google Scholar]
  20. Reaven G. M. The kidney: an unwilling accomplice in syndrome X. Am J Kidney Dis. 1997 Dec;30(6):928–931. doi: 10.1016/s0272-6386(97)90106-2. [DOI] [PubMed] [Google Scholar]
  21. Shahinfar S., Simpson R. L., Carides A. D., Thiyagarajan B., Nakagawa Y., Umans J. G., Parks J. H., Coe F. L. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int. 1999 Nov;56(5):1879–1885. doi: 10.1046/j.1523-1755.1999.00739.x. [DOI] [PubMed] [Google Scholar]
  22. Soffer B. A., Wright J. T., Jr, Pratt J. H., Wiens B., Goldberg A. I., Sweet C. S. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension. 1995 Jul;26(1):112–117. doi: 10.1161/01.hyp.26.1.112. [DOI] [PubMed] [Google Scholar]
  23. Sweet C. S., Bradstreet D. C., Berman R. S., Jallard N., Saenz A., Weidler D. J. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens. 1994 Dec;7(12):1035–1040. doi: 10.1093/ajh/7.12.1035. [DOI] [PubMed] [Google Scholar]
  24. Takahashi S., Moriwaki Y., Yamamoto T., Tsutsumi Z., Ka T., Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis. 2003 Jun;62(6):572–575. doi: 10.1136/ard.62.6.572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron. 1991;59(3):364–368. doi: 10.1159/000186593. [DOI] [PubMed] [Google Scholar]
  26. Würzner G., Gerster J. C., Chiolero A., Maillard M., Fallab-Stubi C. L., Brunner H. R., Burnier M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens. 2001 Oct;19(10):1855–1860. doi: 10.1097/00004872-200110000-00021. [DOI] [PubMed] [Google Scholar]
  27. Yamamoto T., Moriwaki Y., Takahashi S., Tsutsumi Z., Hada T. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol. 2001 Oct;28(10):2294–2297. [PubMed] [Google Scholar]
  28. Yamamoto T., Moriwaki Y., Takahashi S., Tsutsumi Z., Hada T. Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxypurinol and purine bases. J Rheumatol. 2000 Sep;27(9):2232–2236. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES